Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Autifony Therapeutics in Collaboration and Option Deal with Boehringer Ingelheim

December 21, 2017

LONDON—Covington represented Autifony Therapeutics Limited in connection with an option and asset purchase agreement with Boehringer Ingelheim (BI), with respect to Autifony's Kv3.1/3.2 positive modulator platform.

This agreement provides BI with an exclusive option to acquire Autifony’s Kv3.1/3.2 positive modulator platform, including Autifony's lead compound that is currently being evaluated in two Phase Ib studies. BI will pay Autifony an upfront option fee of €25 million, with the possibility of further payments of up to €17.5 million during the option period based on the achievement of short term milestones. The total potential value of the deal may reach up to €627.5 million upon reaching development and pre-commercialization milestones once BI has exercised its option.

Autifony is an independent UK-based biotechnology company formed in 2011, focused on the development of medicines to treat serious diseases of the central nervous system, including schizophrenia, Fragile X syndrome, and hearing disorders.

The Covington team included Daniel Pavin, Winsome Cheung, James Gubbins, Guy Dingley, Chris Bracebridge, Miranda Cole, and Richard Surtees.


Share this article: